盐酸法舒地

GMP; 

Fasudil

CAS Registry Number: 103745-39-7

CAS Name: Hexahydro-1-(5-isoquinolinylsulfonyl)-1H-1,4-diazepine

Additional Names: N-(5-isoquinolinesulfonyl)-1,4-perhydrodiazepine; 1-(5-isoquinolinesulfonyl)homopiperazine

Molecular Formula: C14H17N3O2S

Molecular Weight: 291.37

Percent Composition: C 57.71%, H 5.88%, N 14.42%, O 10.98%, S 11.00%

Literature References: Intracellular calcium antagonist. Prepn: H. Hidaka, T. Sone, EP 187371; eidem, US 4678783 (1986, 1987 both to Asahi); A. Morikawa et al., Chem. Pharm. Bull. 40, 770 (1992). Pharmacology: T. Asano et al., Br. J. Pharmacol. 98, 1091 (1989). Mechanism of action: idem et al., J. Pharmacol. Exp. Ther. 241, 1033 (1987). Clinical trials: M. Shibuya et al., J. Neurosurg. 76, 571 (1992). Acute toxicity: H. Koga et al., Yakuri to Chiryo 20, S1433 (1992), C.A. 117, 226005b (1992). Review of pharmacology and clinical evaluation: M. Shirotani et al., Cardiovasc. Drug Rev. 10, 333-357 (1992).

 

Derivative Type: Hydrochloride

CAS Registry Number: 105628-07-7

Manufacturers' Codes: AT-877; HA-1077

Trademarks: Eril (Asahi)

Molecular Formula: C14H17N3O2S.HCl

Molecular Weight: 327.83

Percent Composition: C 51.29%, H 5.53%, N 12.82%, O 9.76%, S 9.78%, Cl 10.81%

Properties: Crystals from water, mp 220.5°. Also reported as white crystalline powder, mp 219.3° (Shirotani). Sol in water up to 2 ´ 10-2M at pH 5.0-7.0. LD50 in mice, rats (mg/kg): 67.5, 59.9 i.v.; 124.5, 123.2 s.c.; 273.9, 335.0 orally (Koga).

Melting point: mp 220.5°; mp 219.3° (Shirotani)

Toxicity data: LD50 in mice, rats (mg/kg): 67.5, 59.9 i.v.; 124.5, 123.2 s.c.; 273.9, 335.0 orally (Koga)

 

Therap-Cat: Vasodilator (cerebral).

Keywords: Vasodilator (Cerebral).

天津红日药业股份有限公司成立于1996年，于2000年进行股份制改造，2009年10月作为国内首批、天津首家企业在深证证券交易所创业板挂牌上市。（股票代码300026）。 公司自上市后连续荣登《福布斯》中国潜力企业榜、2013年度上市公司金牛奖百强综合榜，荣获2013年度金牛最佳创业成长公司、最具投资价值上市公司、中国最具竞争力医药上市公司20强、2013中国创业板上市公司十佳管理团队等殊荣。 产品包括：现代中药血必净注射液，盐酸法舒地尔口服制剂以及 抗肿瘤类、免疫调节类、血液类、神经类、麻醉类、呼吸类、血管类等原料药和中间体； Tianjin Chase Sun Pharmaceutical Co. Ltd was founded in 1996 and the joint-stock transformation was